

# Dominican Republic

## Tuberculosis profile

Population 2016

11 million

| Estimates of TB burden*, 2016 | Number (thousands) | Rate (per 100 000 population) |
|-------------------------------|--------------------|-------------------------------|
| Mortality (excludes HIV+TB)   | 0.56 (0.24–1)      | 5.2 (2.3–9.5)                 |
| Mortality (HIV+TB only)       | 0.49 (0.35–0.64)   | 4.6 (3.3–6)                   |
| Incidence (includes HIV+TB)   | 6.4 (4.9–8.2)      | 60 (46–77)                    |
| Incidence (HIV+TB only)       | 1.5 (1.1–2)        | 14 (11–19)                    |
| Incidence (MDR/RR-TB)**       | 0.42 (0.3–0.55)    | 4 (2.9–5.1)                   |

Estimated TB incidence by age and sex (thousands)\*, 2016

|         | 0-14 years       | > 14 years    | Total         |
|---------|------------------|---------------|---------------|
| Females | 0.37 (0.27–0.46) | 2 (1.5–2.6)   | 2.4 (1.8–3)   |
| Males   | 0.38 (0.28–0.48) | 3.7 (2.7–4.6) | 4 (3–5.1)     |
| Total   | 0.75 (0.55–0.94) | 5.7 (4.2–7.2) | 6.4 (4.9–8.2) |

TB case notifications, 2016

|  |       |
|--|-------|
| Total cases notified                                   | 4 476 |
| Total new and relapse                                  | 4 235 |
| - % tested with rapid diagnostics at time of diagnosis |       |
| - % with known HIV status                              | 88%   |
| - % pulmonary  | 88%   |
| - % bacteriologically confirmed among pulmonary        | 63%   |

Universal health coverage and social protection

|  |                 |
|--|-----------------|
| TB treatment coverage (notified/estimated incidence), 2016             | 66% (52–87)     |
| TB patients facing catastrophic total costs                            |                 |
| TB case fatality ratio (estimated mortality/estimated incidence), 2016 | 0.17 (0.1–0.25) |

TB/HIV care in new and relapse TB patients, 2016

|   | Number | (%) |
|---|--------|-----|
| Patients with known HIV-status who are HIV-positive | 893    | 24% |
| - on antiretroviral therapy                         | 376    | 42% |

| Drug-resistant TB care, 2016                                | New cases      | Previously treated cases  | Total number*** |
|---|----------------|---------------------------|-----------------|
| Estimated MDR/RR-TB cases among notified pulmonary TB cases |                |                           | 290 (230–360)   |
| Estimated % of TB cases with MDR/RR-TB                      | 2.9% (1.4–4.5) | 34% (28–41)               |                 |
| % notified tested for rifampicin resistance                 | 7%             | 36%                       | 527             |
| MDR/RR-TB cases tested for resistance to second-line drugs  |                |                           | 98              |
| Laboratory-confirmed cases                                  |                | MDR/RR-TB: 107, XDR-TB: 3 |                 |
| Patients started on treatment ****                          |                | MDR/RR-TB: 140, XDR-TB: 1 |                 |

| Treatment success rate and cohort size                          | Success | Cohort |
|---|---------|--------|
| New and relapse cases registered in 2015                        | 80%     | 4 468  |
| Previously treated cases, excluding relapse, registered in 2015 | 63%     | 201    |
| HIV-positive TB cases registered in 2015                        | 65%     | 909    |
| MDR/RR-TB cases started on second-line treatment in 2014        | 50%     | 100    |
| XDR-TB cases started on second-line treatment in 2014           |         | 0      |

TB preventive treatment, 2016

|   |                |
|---|----------------|
| % of HIV-positive people (newly enrolled in care) on preventive treatment                                   | 20%            |
| % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment | 100% (100–100) |

TB financing, 2017

|   |    |
|---|----|
| National TB budget (US\$ millions)                            | 15 |
| Funding source: 65% domestic, 19% international, 17% unfunded |    |


\* Ranges represent uncertainty intervals

\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history


\*\*\*\* Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016




Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



— Unfunded  
— Funded internationally  
— Funded domestically